Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.

David Meek bought Bluebird Bio last year for the pharma industry equivalent of loose change. 

The company was on the brink of bankruptcy. In 12 months, he says, it’s been transformed. 

In a swaggering  interview, one of the first he’s given since the deal, Meek lambasted competitors and claimed the company would dominate the market for sickle cell disease gene therapies for years to come. By 2030, he said the company — now rebranded as Genetix — would be treating 1,000 patients per year. 

1. 

   General Assignment Reporter

   Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.